§ 01

Overview

Muscle Relaxants

Muscle Relaxants

Mechanism of Action Diagram

Muscle relaxants are broadly divided into two pharmacological classes: antispasmodic agents (used for muscle spasm associated with musculoskeletal conditions such as myofascial pain syndrome) and antispasticity agents (used for increased muscle tone from upper motor neuron conditions such as multiple sclerosis, spinal cord injury, and cerebral palsy). For the treatment of myofascial trigger points, the antispasmodic class is the clinically relevant group.

These medications work centrally — at the level of the spinal cord and brainstem — to reduce muscle tone. They do not directly relax muscle fibers at the peripheral level. Their primary role in myofascial pain management is to reduce the heightened muscle tone and spasm that accompanies acute exacerbations, particularly when pain disrupts sleep or limits participation in physical therapy. They are most effective when used as short-term adjuncts combined with analgesics (typically NSAIDs) and active physical therapy.

Most muscle relaxants work centrally in the brain and spinal cord, not directly on the muscle — which is why they cause drowsiness.

Muscle relaxants are not recommended as monotherapy for chronic myofascial pain syndrome. Their value lies in creating a therapeutic window — reducing spasm and improving sleep — that enables the patient to engage more effectively in the stretching, strengthening, postural correction, and manual therapy interventions that produce lasting improvement.

§ 02

Mechanism of Action

Each class of muscle relaxant acts through a distinct pharmacological mechanism, though all share the common endpoint of reducing central drive for muscle contraction.

Mechanism of Action

Mechanism of Action

Mechanism Diagram

Central-Acting Antispasmodics

Reduce polysynaptic reflexes in the spinal cord and brainstem. These agents do not directly relax skeletal muscle fibers at the peripheral level — instead, they reduce the central nervous system drive that maintains excessive muscle contraction. By dampening the facilitory descending pathways, they lower the baseline muscle tone and reduce the sustained contraction characteristic of taut bands in myofascial trigger points.

Cyclobenzaprine (TCA-related)

Structurally related to tricyclic antidepressants (TCAs). Reduces tonic somatic motor activity primarily by acting at the brainstem level, decreasing gamma and alpha motor neuron activity. Also has significant serotonergic effects that improve sleep architecture — particularly increasing Stage 4 (deep) sleep — which is often disrupted in myofascial pain syndrome. The most extensively studied muscle relaxant for Myofascial Pain Syndrome.

Tizanidine (Alpha-2 Agonist)

An alpha-2 adrenergic agonist that acts at the spinal cord level. Reduces the release of excitatory amino acids (glutamate, aspartate) from spinal interneurons, suppressing polysynaptic reflex activity. This mechanism provides both antispastic (for upper motor neuron conditions) and antispasmodic (for musculoskeletal spasm) properties. Causes less muscle weakness than other agents at equi-effective doses.

Methocarbamol (CNS Depressant)

Exact mechanism of action remains unclear. Believed to produce muscle relaxation through generalized CNS depression of polysynaptic reflexes rather than through a specific receptor-mediated mechanism. May have carbamic acid ester properties that contribute to its sedative effects. Considered a weaker muscle relaxant than cyclobenzaprine or tizanidine.

Orphenadrine (Anticholinergic)

Exerts its muscle relaxant effect through a combination of anticholinergic (muscarinic receptor blockade) and antihistaminic (H1 receptor blockade) activity. Also demonstrates a weak analgesic effect independent of its muscle relaxant properties, possibly through NMDA receptor modulation. Available in some countries as a combination product with dipyrone (metamizole) and caffeine.

Baclofen (GABA-B Agonist)

A structural analogue of GABA that acts as a selective GABA-B receptor agonist. Inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by hyperpolarizing primary afferent terminals and inhibiting the release of excitatory neurotransmitters. Primarily classified as an antispasticity agent but may help myofascial pain associated with central sensitization.

Diazepam (Benzodiazepine)

A GABA-A receptor potentiator that enhances the inhibitory effect of GABA throughout the CNS. Produces muscle relaxation through multiple mechanisms: reduction of polysynaptic reflexes at the spinal cord level, suppression of the reticular activating system, and reduction of anxiety-mediated muscle guarding. Effective but high abuse potential limits its role to acute severe spasm only.
§ 03

Individual Drug Profiles

Cyclobenzaprine

Strong

Flexeril, Amrix (ER)

Dosing5-10 mg TID (immediate-release) or 15-30 mg once daily (extended-release). Start low at 5 mg at bedtime and titrate.
Half-Life18 hours (up to 33 hours in elderly)
Advantages
  • Most studied muscle relaxant for myofascial pain
  • Meta-analysis (Browning et al. 2001, Arch Intern Med): NNT ~3 for global symptom improvement at 14 days; OR 4.7 (95% CI 2.7-8.1) for benefit vs placebo
  • Improves sleep architecture (increases Stage 4 deep sleep)
  • Available in extended-release formulation for once-daily dosing
  • Well-established safety profile over decades of use
Disadvantages
  • Significant drowsiness (common)
  • Dry mouth, dizziness, constipation
  • Anticholinergic effects (caution in elderly, BPH, glaucoma)
  • Serotonin syndrome risk with SSRIs/SNRIs (rare)
  • Not recommended for use beyond 2-3 weeks (limited long-term data)
  • Long half-life leads to next-day sedation
Best For →Best for: Acute myofascial pain flares with disrupted sleep. First-line choice for nighttime use when insomnia accompanies myofascial pain.

Tizanidine

Moderate

Zanaflex

Dosing2-8 mg TID, max 36 mg/day. Start at 2 mg at bedtime, titrate slowly over 1-4 weeks.
Half-Life2.5 hours
Advantages
  • Shorter half-life allows better daytime functioning
  • Less sedating than cyclobenzaprine at low doses
  • Both antispastic and antispasmodic properties
  • Demonstrates antinociceptive effects independent of muscle relaxation
  • Established efficacy for acute musculoskeletal pain (Berry & Hutchinson, 1988, J Int Med Res — acute low-back pain). Direct myofascial pain evidence is more limited and supported mainly by smaller trials and observational use.
Disadvantages
  • Hepatotoxicity risk: must monitor liver function tests (LFTs)
  • Significant CYP1A2 drug interactions (avoid with fluvoxamine, ciprofloxacin)
  • Hypotension, especially with dose increases
  • Rebound hypertension if stopped abruptly at high doses
  • Dry mouth (very common)
  • Shorter duration requires TID dosing for 24-hour coverage
Best For →Best for: Daytime use when alertness is needed. Preferred when cyclobenzaprine causes excessive daytime sedation.

Methocarbamol

Limited

Robaxin

Dosing750-1500 mg QID initially (first 48-72 hours), then reduce to 750 mg QID as maintenance. Max 4500 mg/day for maintenance.
Half-Life1-2 hours
Advantages
  • Milder sedation profile than cyclobenzaprine
  • Available over-the-counter in some countries (Canada, UK, Australia)
  • Injectable formulation available for acute settings
  • Low abuse potential
  • Generally well tolerated in most patients
Disadvantages
  • Weaker efficacy compared to cyclobenzaprine and tizanidine
  • Very short half-life requires frequent dosing (QID)
  • Limited evidence specifically for myofascial pain (most data for acute back spasm)
  • May discolor urine (brown, black, or green) — harmless but alarming
  • High pill burden with QID dosing
Best For →Best for: Mild-to-moderate acute muscle spasm when stronger agents cause intolerable sedation. Good option for patients sensitive to anticholinergic effects.

Orphenadrine

Limited

Norflex; combination products (orphenadrine + dipyrone + caffeine) in some countries

Dosing100 mg BID (oral) or 60 mg IV/IM BID. Combination products: 1-2 tablets up to TID.
Half-Life14-16 hours
Advantages
  • Mild analgesic properties independent of muscle relaxation
  • Long half-life allows BID dosing
  • Combination product (orphenadrine + dipyrone + caffeine) popular in Latin America and parts of Europe
  • Caffeine component may partially offset sedation
  • Some evidence for NMDA receptor modulation (potential for central sensitization)
Disadvantages
  • Anticholinergic side effects: dry mouth, urinary retention, blurred vision, constipation
  • Tachycardia possible
  • Contraindicated in glaucoma, myasthenia gravis, GI/GU obstruction
  • High anticholinergic burden — problematic in elderly
  • Limited clinical trial data for myofascial pain specifically
  • Dipyrone component (in combination products) carries rare risk of agranulocytosis
Best For →Best for: Acute episodes with muscle spasm. Widely used in Latin America and parts of Europe. Reasonable option when combined analgesic + relaxant effect desired.

Baclofen

Limited

Lioresal

Dosing5-20 mg TID. Start at 5 mg TID and titrate by 5 mg every 3 days. Max 80 mg/day.
Half-Life3-4 hours
Advantages
  • Primary indication is spasticity, but may benefit central sensitization in chronic myofascial pain
  • Well-studied mechanism (GABA-B agonism)
  • Intrathecal formulation available for severe, refractory cases
  • May improve sleep at higher doses
  • Lower anticholinergic burden than cyclobenzaprine or orphenadrine
Disadvantages
  • NEVER stop abruptly — withdrawal can cause seizures, hallucinations, and potentially fatal hyperthermia
  • Drowsiness, dizziness, weakness are common
  • Limited evidence specifically for myofascial pain (stronger for spasticity)
  • Requires slow titration and taper
  • Cognitive effects at higher doses
  • Urinary retention possible
Best For →Best for: Patients with concurrent spasticity conditions (MS, spinal cord injury) who also have myofascial pain. May help when central sensitization is a prominent feature.
§ 04

Clinical Evidence for myofascial pain

Cyclobenzaprine

Strong

The strongest evidence base among muscle relaxants for myofascial pain. The meta-analysis by Browning et al. (2001, Arch Intern Med) evaluated 14 randomized controlled trials of cyclobenzaprine for acute back pain and found a statistically significant improvement compared to placebo, with an odds ratio of 4.7 (95% CI 2.7-8.1) for global symptom improvement and a number needed to treat (NNT) of approximately 3 at 14 days. Multiple additional trials have confirmed its superiority over placebo for acute musculoskeletal pain with spasm.

Tizanidine

Moderate

Direct evidence for myofascial pain syndrome is more limited than for cyclobenzaprine. The original Berry & Hutchinson trials (1988, J Int Med Res, PMIDs 2967780 and 2967781) established tizanidine’s effectiveness for acute low-back pain rather than for myofascial pain specifically. Smaller subsequent studies and review articles (e.g., Malanga 2008, Expert Opin Pharmacother) describe clinical effectiveness in muscle spasm and selected pain syndromes including myofascial pain, particularly when cyclobenzaprine is poorly tolerated. Its alpha-2 agonist mechanism provides an independent antinociceptive component that may contribute to pain relief beyond muscle relaxation alone.

Combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Strong

Several studies suggest additive benefit when muscle relaxants are combined with NSAIDs. The combination addresses both the peripheral inflammatory/nociceptive component (NSAID) and the central muscle spasm/tone component (muscle relaxant). This combination may be more effective than either agent alone in some cases of acute myofascial pain with spasm, though the overall evidence base remains limited.

Short-term vs Long-term

Important Caveat

The short-term benefit of muscle relaxants for myofascial pain is well-established across multiple studies (2-4 week duration). However, evidence supporting long-term use (beyond 4 weeks) is limited. Most clinical guidelines recommend time-limited use with regular reassessment. The role of muscle relaxants is as an adjunct to physical therapy and active rehabilitation, not as monotherapy for chronic myofascial pain.

§ 05

Important Safety Considerations

§ 06

Comparison Grid

Comparison Grid

Comparison Grid

Comparison Chart
Property
CyclobenzaprineTizanidineMethocarbamolOrphenadrine

Sedation

High
Moderate
Mild
Moderate

Efficacy for myofascial pain

Strong
Moderate
Mild-Moderate
Limited Data

Half-Life

18 h
2.5 h
1-2 h
14-16 h

Dosing Frequency

TID or QD (ER)
TID
QID
BID

Abuse Potential

None
None
None
Low

Anticholinergic Load

Moderate
Low
Low
High

Hepatotoxicity

Rare
Monitor LFTs
Rare
Rare

Best Timing

Bedtime
Daytime
Any
Any

Sleep Improvement

Significant
Mild
Minimal
Minimal
§ 07

Practical Prescribing for myofascial pain

First Choice: Low-Dose Cyclobenzaprine at Bedtime

Start with cyclobenzaprine 5 mg at bedtime for 2-3 weeks. This leverages its sleep-improving properties (increases Stage 4 deep sleep) while minimizing daytime sedation. The Browning 2001 meta-analysis NNT of approximately 3 for global symptom improvement at 14 days supports its role as first-line. If well tolerated but insufficient, increase to 10 mg at bedtime. Extended-release 15 mg daily is an alternative for patients needing around-the-clock coverage.

If Daytime Coverage Needed: Add Tizanidine

When daytime muscle spasm and pain require treatment but cyclobenzaprine causes excessive sedation during waking hours, add or switch to tizanidine 2 mg during the day. Titrate slowly to 4-8 mg as needed. Monitor liver function tests at baseline and periodically. Avoid in patients taking CYP1A2 inhibitors (fluvoxamine, ciprofloxacin).

Combine with NSAID for Acute Flares

For acute myofascial pain exacerbations with significant pain and inflammation, combine the muscle relaxant with an NSAID (naproxen 250-500 mg BID or ibuprofen 400-600 mg TID). Multiple studies demonstrate additive benefit. The NSAID addresses peripheral nociceptive input while the muscle relaxant reduces central muscle tone. Limit NSAID duration per GI and renal safety guidelines.

Always Pair with Active Physical Therapy

Muscle relaxants should NEVER be used as monotherapy for myofascial pain. They are an adjunct that creates a therapeutic window — by reducing muscle spasm and improving sleep, they enable the patient to participate more effectively in stretching, strengthening, postural correction, and trigger point-specific manual therapy. The physical therapy component is what produces lasting improvement.

Taper After 2-4 Weeks and Reassess

At the 2-4 week mark, begin tapering the muscle relaxant and reassess. If physical therapy and self-management strategies are effective, discontinuation is appropriate. If symptoms persist, investigate for perpetuating factors (postural dysfunction, ergonomic issues, sleep disorders, psychosocial stressors) rather than simply continuing the medication indefinitely.
Key Takeaways

  1. Cyclobenzaprine is the best-studied muscle relaxant for myofascial pain (Browning 2001 meta-analysis: NNT ~3 for global improvement at 14 days) — start with 5 mg at bedtime

  2. Tizanidine is the preferred option when daytime alertness is a priority, offering less sedation at low doses

  3. All muscle relaxants should be used SHORT-TERM (2-4 weeks) as adjuncts to physical therapy, not as monotherapy

  4. Combination with NSAIDs provides additive benefit for acute myofascial pain flares and is supported by multiple studies

  5. Avoid carisoprodol (controlled substance metabolite) and limit diazepam use to acute severe spasm only

  6. Elderly patients are at heightened risk — the Beers Criteria lists most muscle relaxants as potentially inappropriate

  7. Always address perpetuating factors and pair medication with active rehabilitation for lasting outcomes

  8. Monitor for serotonin syndrome risk when cyclobenzaprine is combined with SSRIs/SNRIs

Remember:Their value in myofascial pain management is to reduce muscle spasm and improve sleep in the short term, enabling the patient to engage in the active rehabilitation that produces lasting results. The physical therapy and self-management components of treatment are what ultimately resolve myofascial trigger points.